Most new medicines are first tested elsewhere. And that could cost Europe future innovation

EU PERSPECTIVES - Europe is testing plenty of new medicines—but mostly at the later stages. The earliest, most experimental studies, where drugs are first tried in humans, remain surprisingly scarce. According to Dr Peter Arlett of the European Medicines Agency (EMA), this imbalance could shape the future of medical innovation in the EU. Read more

Photo: Unsplash